Advanced Search
Ding Xiaoyan, Fan Ying, Ma Fei, Li Qing, Wang Jiayu, Yuan Peng, Zhang Pin, Xu Binghe. Analyses on Skeletal-related Events and Prognosis of Postmenopausal Breast Cancer Patients with Bone Metastasis[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 627-631. DOI: 10.3971/j.issn.1000-8578.2012.06.004
Citation: Ding Xiaoyan, Fan Ying, Ma Fei, Li Qing, Wang Jiayu, Yuan Peng, Zhang Pin, Xu Binghe. Analyses on Skeletal-related Events and Prognosis of Postmenopausal Breast Cancer Patients with Bone Metastasis[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 627-631. DOI: 10.3971/j.issn.1000-8578.2012.06.004

Analyses on Skeletal-related Events and Prognosis of Postmenopausal Breast Cancer Patients with Bone Metastasis

More Information
  • Received Date: March 25, 2012
  • Revised Date: April 12, 2012
  • Objective To estimate treatment regimens,prognosis and skeletal-related events(SREs) for post-menopausal breast cancer(BrCa) patients with bone metastases. Methods One hundred and thirty-six post-menopausal BrCa patients with bone metastases were retrospectively reviewed.Clinical pathologic characteristics were analyzed.Moreover,the incidence of SREs was explored. Results In this cohort,the age of 49 patients was ≥60 years(elderly group),and 87 patients was below 60 years(younger group).One hundred and four patients received first-line chemotherapy regimens,and 32 patients received first -line endocrine drugs.The proportion of patients with SREs was increased in the elderly group compared with the younger group,20/49(44.9%) vs.30/87(32.2%) respectively without significant difference(P=0.194).Median overall survival time of all patients was 48.0 months(range,39.1~56.9).The overall survival was notably worse in patients with SREs,compared with patients without SREs(P=0.011).No significant difference was noted in median time of overall survival between elderly group and younger group,50.0 months vs.40.0 months(P=0.689).However,compared with the younger group,the median time of PFS in elderly group was longer,17.0 months vs.11.0 months,but without significant difference (P=0.161). Conclusion No significant differences are observed between elderly group and younger group in PFS or OS.The incidence of SREs is slightly increased by age.The overall survival is remarkably worse in postmenopausal BrCa patients with bone metastases and SREs.SREs increase the risk of death.
  • [1]
    Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300.
    [2]
    Sathiakumar N,Delzell E,Morrisey MA,et al.Mortality following bone metastasis and skeletal-related events among women with breast cancer:a population-based analysis of U.S.Medicarebeneficiaries,1999-2006[J].Breast Cancer Res Treat,2012,131(1):231-8.
    [3]
    Trinkaus M,Simmons C,Myers J,et al.Skeletal-related events(SREs) in breast cancer patientswith bone metastases treated in the nontrial setting[J].Support Care Cancer,2010,18(2):197-203.
    [4]
    Jensen A,Jacobsen JB,Nrgaard M,et al.Incidence of bone metastases and skeletal-relatedevents in breast cancer patients:a population-based cohort study in Denmark[J].BMC Cancer,2011,11:29.
    [5]
    Liu H,Xun P,Chen KX,et al.The trend of cIinical characteristics and pmlmosis of women′s breastcancer 1981-2000[J].Zhonghua Yi Xue Za Zhi,2007,87(34):2405-7.[刘红,荀培,陈可欣,等.天津市近20年女性乳腺癌患者临床病理特点及预后变化趋势分析[J].中华医学杂志,2007,87(34):2405-7.]
    [6]
    DeSantis C,Siegel R,Bandi P,et al.Breast Cancer Statistics,2011[J].CA Cancer J Clin,2011,61(6):409-18.
    [7]
    Koizumi M,Yoshimoto M,Kasumi F,et al.Post-operative breast cancer patients diagnosedwithskeletal metastasis without bone pain had fewer skeletal-related events and deaths thanthosewith bone pain[J].BMC Cancer,2010,10:423.
    [8]
    Machado M,Cruz LS,Tannus G,et al.Efficacy of clodronate,pamidronate,and zoledronate inreducing morbidity and mortality in cancer patients with bone metastasis:a meta-analysis ofrandomized clinical trials[J].Clin Ther,2009,31(5):962-79.
    [9]
    Henk HJ,Kaura S.Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan[J].J Med Econ,2012,15(1):175-84.
    [10]
    Neville-Webbe HL,Gnant M,Coleman RE.Potential anticancer properties of bisphosphonates[J].Semin Oncol,2010,37 Suppl 1:S53-65.
    [11]
    Saad F,Lipton A,Cook R,et al.Pathologic fractures correlate with reduced survival inpatients with malignant bone disease[J].Cancer,2007,110(8):1860-7.
    [12]
    Niikura N,Liu J,Hayashi N,et al.Treatment outcome and prognostic factors for patients withbone-only metastases of breast cancer:a single-institution retrospective analysis[J].Oncologist,2011,16(2):155-64.
    [13]
    Lee SJ,Park S,Ahn HK,et al.Implications of bone-only metastases in breast cancer:favorablepreference with excellent outcomes of hormone receptor positive breast cancer[J].Cancer ResTreat,2011,43(2):89-95.
    [14]
    Yavas O,Hayran M,Ozisik Y.Factors affecting survival in breast cancer patients following bonemetastasis[J].Tumori,2007,93(6):580-6.
    [15]
    Brown JE,Cook RJ,Lipton A,et al.Prognostic factors for skeletal complications from metastaticbone disease in breast cancer[J].Breast Cancer Res Treat,2010,123(3):767-79.
  • Related Articles

    [1]XIE Yuhua, LI Shengjin. Disease Spectrum and Prognosis of Rare Lung Malignancies[J]. Cancer Research on Prevention and Treatment, 2020, 47(6): 432-436. DOI: 10.3971/j.issn.1000-8578.2020.19.1169
    [2]CHEN Ni'na, ZHAO Lei, CAO Bangwei. Cholesterol: A Predictor of Risk and Prognosis of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(9): 847-850. DOI: 10.3971/j.issn.1000-8578.2019.19.0265
    [3]DONG Fei, PANG Meng, ZHENG Dong, ZHEN Jingfei, JING Hongmei. Clinical Characteristics and Prognosis of Primary Thyroid Lymphoma Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(6): 515-518. DOI: 10.3971/j.issn.1000-8578.2019.18.1561
    [4]JING Yaoyao, YANG Hongliang, ZHAO Haifeng, YU Yong, ZHAO Zhigang, WANG Yafei, ZHANG Yizhuo, WANG Xiaofang. Value of Peripheral Blood Cell Count and Its Ratio in Evaluating Prognosis of Newly Diagnosed Multiple Myeloma Patients with Non-bone-related Extramedullary Diseases[J]. Cancer Research on Prevention and Treatment, 2019, 46(5): 456-462. DOI: 10.3971/j.issn.1000-8578.2019.18.1075
    [5]LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
    [6]GUO Jiajia, PENG Yuan, WANG Shu. Prognosis-related Factors of Bilateral Primary Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 150-153. DOI: 10.3971/j.issn.1000-8578.2015.02.011
    [7]LU Xianzhou, LIU Longfei, ZHOU Xiaojun, XIAO Shuai, LONG Jianwu, ZHOU Xian. GPR124 Expression and Its Relationship with Prognosis in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(10): 1082-1086. DOI: 10.3971/j.issn.1000-8578.2014.10.006
    [8]MAO Zhiyuan, XIONG Mei, REN Li, LI Dechang, YUE Ying, ZHENG Jichun. Pathological Factors for Prognosis of Extrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(07): 777-780. DOI: 10.3971/j.issn.1000-8578.2014.07.019
    [9]GE Pei-lin, ZHONG Yun-ping. Prognosis Analysis of Low Grade Gliomas[J]. Cancer Research on Prevention and Treatment, 2005, 32(07): 438-439. DOI: 10.3971/j.issn.1000-8578.1262
    [10]WANG Jian-liu, Fu Qi, et al, . Treatment and Prognosis of Endometrial Carcinoma in Advanced Stage[J]. Cancer Research on Prevention and Treatment, 2001, 28(03): 214-216. DOI: 10.3971/j.issn.1000-8578.2150

Catalog

    Corresponding author: Xu Binghe, xubinghe@medmail.com.cn

    1. On this Site
    2. On Google Scholar
    3. On PubMed
    Article views (3561) PDF downloads (868) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return